Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
| Market Cap | 9.01B+104.2% |
| Revenue (ttm) | 42.16M+2928.4% |
| Net Income | -501.61M-35.6% |
| EPS | -5.05-22.9% |
| Shares Out | 106.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 0 |
| Open | 84.95 |
| Previous Close | 84.95 |
| Day's Range | 84.95 - 84.95 |
| 52-Week Range | 32.30 - 85.01 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | 84.86(-0.11%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CRNX stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CRNX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert CisnerosHouse / D | Sale$15.00K – $50.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Sale$15.00K – $50.00K | Jul 30, 2026 |
| Gilbert Ray CisnerosHouse / D | Sale$15.00K – $50.00K | Jul 29, 2026 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 3, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 3, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Mar 2, 2026 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Apr 17, 2025 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Apr 17, 2025 |
Recently reported changes in CRNX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CRNX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CRNX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CRNX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CRNX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CRNX
| ETF | Est. Holding Size |
|---|---|
| MNTLTema Neuroscience And Mental Health ETF | $363.76K |
| NSCSNuveen Small Cap Select | $43.32K |
| VFLQVanguard U.S. Liquidity Factor ETF | $40.48K |
| PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | $29.69K |
| FSMOFidelity Fundamental Small-Mid Cap ETF | $1.53K |
| FFSMFidelity Fundamental Small-Mid Cap ETF | $1.53K |
Estimated from each fund’s disclosed top holdings × AUM
CRNX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CRNX’s recent data — informational, not investment advice